Imricor Medical Systems (ASX:IMR) said the Oklahoma Heart Institute (OHI) will serve as the fourth US site for its Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) clinical trial, according to a Tuesday filing with the Australian bourse.
The trial is investigating the safety and efficacy of radio-frequency ablation of ventricular tachycardia performed with the company's product, Vision-MR Ablation Catheter 2.0, the company said in an August 2023 statement.
The company expects to start procedures at OHI in March, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments